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Sarcoidosis is a systemic nonnecrotizing granulo-
matous disease, the etiology of which is suspected to
be immune mediated.1 Hematopoietic stem cell
transplantation (HSCT) is effective in cases of
immune diseases because of a beneficial graft-
versus-autoimmune (GVA) reaction similar to the
graft-versus-leukemia reaction.2-4 We report the
case of a long-lasting corticosteroid-dependent
sarcoidosis complicated by acute myeloid leukemia
(AML) treated with allogenic HSCT. After this
treatment, sarcoidosis resolved with no relapse after
a long follow-up period.CASE REPORT
A 55-year-old woman was referred to our unit for
arthritis and cutaneous eruption. She had a 2-year
history of joint pain in her knees, wrists, and ankles
with morning stiffness and had several episodes of
anterior uveitis. Examination found metacarpopha-
langeal arthritis and multiple tiny infiltrated papules
on her back, arms, and legs (Fig 1). Cutaneous
biopsy found a disperse inflammatory infiltrate
composed of mononuclear cells and small
nonnecrotizing circumscribed granulomas with
epithelioid cells in the papillary dermis (Fig 2).
Infection was ruled out by negative results of special
staining, bacterial skin culture, and negative
intradermal tuberculin test. A visceral evaluation
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of angiotensin-converting enzyme were within
normal ranges. Based on the physical exam and
laboratory findings, we diagnosed lichenoid
sarcoidosis. Antimalarial medications, methotrexate,
cyclines, and thalidomide were successively tried
with limited improvement. Systemic corticosteroids
induced remission but were associated with
relapses after dose reduction. Finally, low doses
of corticosteroids (7 mg/d) combined with
methotrexate (15 mg/wk) helped achieve remission
but these doses could not be reduced. Eight years
after the diagnosis, blood investigations found
pancytopenia with blastic cells in peripheral blood.
Bone marrow biopsy found an excess of blasts with
precursor cells increasing, trisomy 8, and loss of
17p/TP53 on cytogenetic analysis, leading to the
diagnosis of primitive myelofibrosis progressing
to AML. Umbilical cord blood HSCT after
nonablative regimen with fludarabine (40 mg/m2)
and cyclophosphamide (50 mg/kg) were given.
On completion of treatment, the patient was
asymptomatic, and full remission was obtained forJAAD Case Reports 2016;2:408-10.
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Fig 1. Clinical presentation of the cutaneous sarcoidosis
shows lichenoid eruption on back and arms.
Fig 2. Pathologic changes on skin biopsy show a granu-
lomatous dermatitis with epithelioid cells in the dermis
and a moderate lymphomatous infiltrate. (Hematoxylin-
eosin stain; original magnification: 320.)
Fig 3. Clinical remission of the sarcoidosis after allogenic
HSCT.
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she presented with cutaneous graft-versus-host
disease (GvHD), which was well controlled using
mycophenolatemofetil and everolimus for 3months.
Five months after allogenic HSCT, all immunosup-
pressive drugs were stopped without any recurrence
of sarcoidosis, which, after 4 years of follow-up,
remains asymptomatic (Fig 3).DISCUSSION
Sarcoidosis has no well-defined diagnostic
criteria, and a reliable diagnosis is difficult when
the lungs are spared.1 Our patient had a granuloma-
tous dermatitis, which could have been granuloma
annulare with a histological sarcoidal pattern.
However, the lack of necrobiosis or mucin on skin
biopsy and the associated with anterior uveitis and
arthritis are likely in favor of lichenoid sarcoidosis.
Studies suggest that sarcoidosis is caused by
excessive helper T cell 1 (Th1)-like host response to
an unidentified constant antigen.1,5 Overstimulated
macrophages and CD41 T cells induce anexaggerated local production of Th1 mediators
leading to granulomatous formation. Moreover, the
reduced activity of regulatory lymphocytes allows
this inflammatory amplified Th1 immune response to
persist.5 This way, sarcoidosis is seen as an immune-
mediated disease. Cutaneous sarcoidosis is usually
managed with antimalarial drugs. Additional
therapies such as corticosteroids, methotrexate, and
cyclines could also be required.6 Despite the use of
these therapies, sarcoidosis was not controlled.
In our case, allogenic HSCT treated the AML
successfully and induced an unexpected complete
remission of the sarcoidosis. This favorable outcome
after the AML treatment could be explained by
(1) the GvHD treatment (everolimus and mycophe-
nolate mofetil), (2) the pretransplant conditioning
(cyclophosphamide and fludarabine), or (3) the GVA
reaction.
Mycophenolate mofetil, used in the GvHD treat-
ment, is reported to be a second-line treatment of
sarcoidosis although with relapses after cessation
and absence of lasting effect.7 Chronologically, our
patient experienced remission of the sarcoidosis
before the GvHD appeared. Thus, the role of the
GvHD treatment appeared less likely to explain the
sarcoidosis remission. The immunosuppressive
effect of the pretransplant conditioning could
have had a beneficial role on the sarcoidosis.
However, no case of sarcoidosis successfully treated
with fludarabine is reported in the literature.
Cyclophosphamide has been used to treat
neurologic or cardiac sarcoidosis, but the results
are heterogeneous, and relapses are frequent.8 In
addition, sarcoidosis occurring after organ transplant
has been reported, highlighting the fact that an
ablative regimen is not unequivocally efficient to
prevent or treat sarcoidosis. As a result, the
pretransplant conditioning alone seems to be
insufficient in explaining the long-lasting remission
of the sarcoidosis in our case. Efficacy of HSCT for
treating immune-mediated diseases was reported
since the late 1990s.2,9 These positive effects could
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Allogenic HSCT is based on the immune reset similar
to autologous HSCT and on an additional correction
of genetic predisposition to disease.2 This way,
allograft could confer a GVA reaction due to the
apoptosis or modulation of autoreactive lympho-
cytes by the nondisease donor lymphocytes.
Allograft could also correct a genetic predisposition
to immune-mediated diseases.2-4,9 Herein, we
suggest that this GVA effect was the main mechanism
explaining the long-lasting sarcoidosis remission
after replacement of the Th1 such as CD41 T cells
of the patient by the nonedisease-prone hemato-
poietic stem cells from the normal donor. This
hypothesis is highlighted by a case of sarcoidosis
remission after donor lymphocytes infusions.4
Despite their potential for curing, allogenic HSCTs
are usually associated with mortality because of the
conditioning regimen and GvHD, and should only
be considered in selected cases of refractory
sarcoidosis. Sarcoidosis after HSCT has been
reported in 10 cases.10 More studies are needed to
determine whether these cases were caused by a
transmission from the donor or also to an abnormal
immunologic response.10
We report herein a unique case of sarcoidosis
remission after allogenic HSCT, suggesting a
beneficial GVA effect on sarcoidosis. Although thisreport leads to more questions than answers, we
suggest that T lymphocyte therapies could be a
treatment for refractory sarcoidosis in selected cases.
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